To inhibit or to boost the ATP/P2RX7 pathway to fight cancer, that is the question

Serena Janho Dit Hreich (1, 2) , Jonathan Benzaquen (1, 2) , Paul Hofman (1, 2, 3) , Valérie Vouret- Craviari (1, 2)

1 IRCAN - Institut de Recherche sur le Cancer et le Vieillissement
2 UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice]
3 CHU - Hôpital Pasteur [Nice]

Despite new biological insights and recent therapeutic advances, many tumors remain at baseline during treatments. Therefore, there is an urgent need to find new therapeutic strategies to improve the care of patients with solid tumors. P2RX7 receptor (P2XR7), an ATPgated ion channel characterized by its ability to form large pore within the cell membrane, is described by most of the investigators as a "chef d'orchestre" of the antitumor immune response. The purpose of this review is to detail the recent information concerning different cellular mechanisms linking P2RX7 to hallmarks of cancer and to discuss different progresses in elucidating how activation of the ATP/P2RX7/NLRP3/IL-18 pathway is a very promising approach to fight cancer progression by increasing antitumor immune responses.

Mots clés: purinergic signalling; P2X7; immunotherapies; tumors; antitumor immunity; ectonucleases

Domaines: Cancer; Immunité innée; Immunothérapie

Serena Janho Dit Hreich, Jonathan Benzaquen, Paul Hofman, Valérie Vouret- Craviari. To inhibit or to boost the ATP/P2RX7 pathway to fight cancer, that is the question. Purinergic Signalling, inPress, ⟨10.1007/s11302-021-09811-9⟩. ⟨hal-03349736⟩